



FOR IMMEDIATE RELEASE

Contact: Mark N. Schwartz, CEO
(651) 687-9999

Hypertension Diagnostics Announces FY 2008 Second Quarter Results

ST. PAUL, MN – February 14, 2008 – Hypertension Diagnostics, Inc. (OTC: HDII.OB), today announced financial results for the second quarter of fiscal year 2008 ended December 31, 2007.

Revenue for the second quarter ended December 31, 2007 totaled \$145,662 compared to \$548,723 in the prior year's second quarter ended December 31, 2006, a 73.5% decrease. The Company's net income was \$165,448 for the second quarter or \$.00 per share compared with a net loss of \$225,404 for the prior year's second quarter or \$(-.01) per share. Included in net income of \$165,448 for the second quarter are total non-cash benefits (benefits or charges associated mainly with stock based compensation, depreciation, stock options) of \$252,870. Stock based compensation, which is a non-cash charge that relates to the estimated amount due our chief executive officer as part of his compensation for services provided to us, resulted in a benefit of \$283,500 for the quarter ended December 31, 2007 compared to an expense of \$139,125 for the quarter ended December 31, 2006. The negative expense or benefit for the quarter ended December 31, 2007 results from the decrease in the Company's stock price during the quarter ended December 31, 2007. This negative expense caused the Company to record net income for the quarter ended December 31, 2007. For the quarter ended December 31, 2007, the company would have incurred a net loss of \$118,052 on a pro-forma basis after excluding the stock based compensation benefit. Included in the net loss of \$225,404 for the prior year's second quarter were total non-cash charges of \$166,072. For the quarter ended December 31, 2006, the company would have incurred a net loss of \$86,279 on a pro forma basis after excluding the stock based compensation expense.

The Company reported a cash balance of \$1,315,781 on December 31, 2007, a decrease from \$1,467,575 reported on September 30, 2007.

For the six month period ended December 31, 2007, total revenue was \$292,014, compared to \$971,208 for the six month period ended December 31, 2006, a 69.9% decrease. For the six month period ended December 31, 2007, the Company incurred a net loss of \$290,760, or \$(-.01) per share, compared with a net loss of \$413,485, or \$(-.01) per share, for the six month period ended December 31, 2006.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 2007 Annual Report on Form 10-KSB, and subsequent Quarterly Reports on Form 10-QSB, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.

– more –

Hypertension Diagnostics, Inc.
Summary Financial Data

Statements of Operations (Unaudited)

	Three Months Ended December 31		Six Months Ended December 31	
	2007	2006	2007	2006
Revenue:				
Equipment sales	\$ 91,705	\$ 476,505	\$ 183,635	\$ 809,806
Equipment rental	35,558	65,407	81,785	140,585
Service/contract income	18,399	6,811	26,594	20,817
	<u>145,662</u>	<u>548,723</u>	<u>292,014</u>	<u>971,208</u>
Cost of Sales	<u>12,113</u>	<u>13,330</u>	<u>14,441</u>	<u>33,575</u>
Gross Profit	133,549	535,393	277,573	937,633
Selling, general and administrative expenses	(17,963)	774,954	597,022	1,386,960
Gain on sale of property and equipment	-	-	-	(8,099)
Total Expense	<u>(17,963)</u>	<u>774,954</u>	<u>597,022</u>	<u>1,378,861</u>
Operating Loss	151,512	(239,561)	(319,449)	(441,228)
Other Income:				
Interest income	13,936	14,157	28,689	27,743
Total Other Income	<u>13,936</u>	<u>14,157</u>	<u>28,689</u>	<u>27,743</u>
Net (Loss) Income	<u>\$ 165,448</u>	<u>\$ (225,404)</u>	<u>\$ (290,760)</u>	<u>\$ (413,485)</u>
Basic and Diluted Net Loss per Share	\$.00	\$ (.01)	\$ (.01)	\$ (.01)
Weighted Average Shares Outstanding	39,666,835	39,846,547	39,658,077	40,001,826

Balance Sheet Data

	December 31, 2007 (Unaudited)	June 30, 2007 (Audited)
Cash and cash equivalents	\$ 1,315,781	\$ 1,376,632
Total current assets	1,662,092	1,976,825
Total assets	1,691,268	2,020,385
Total current liabilities	487,311	582,124
Accumulated deficit	(26,773,090)	(26,482,330)
Total shareholders' equity	1,184,308	1,426,143
	# # #	

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.
Hypertension Diagnostics, HDI/*PulseWave*, *PulseWave* and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.
Website: www.hdii.com